Tvardi Therapeutics Inc

TVRD is carving an early-stage Stage 1 consolidation after a steep decline, with flat 9/21 EMAs hugging price and subdued volume. The asset sits at extreme oversold levels within a horizontal base range, offering a medium-term bullish mean-reversion opportunity. Short-term timing is neutral due to lack of decisive acceptance or breakout. The recommended posture is to stalk long entries near the EMA cluster and lower boundary, awaiting clear price acceptance above these structural support levels.

• ↑Phase 1 trial saw 60% reduction in disease-relevant immune cells with improved tolerability.
• ↑Cash runway extends to Q4 2026; short-term assets exceed liabilities; zero debt.
• ↓Q1 2026 net loss narrowed to $6.8 M but remains unprofitable.